Oxford Biomedica PLC Director Dealings / Market Share Purchase (5243N)

TIDMOXB

RNS Number : 5243N

Oxford Biomedica PLC

18 January 2019

Director Dealings / Market Share Purchase

Oxford, UK - 18 January 2019: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Andrew Heath, Deputy Chairman and Senior Independent Director of the Group, has purchased 4,000 ordinary shares of 50p each ("Ordinary Shares") in the Company on 17 January 2019 on the London Stock Exchange at a price of 615.5p. Following this purchase Dr. Andrew Heath holds 40,000 shares representing 0.06% of the Company.

2,000 Ordinary Shares were purchased by Dr. Heath's wife (Eva Lackner) and are therefore considered a beneficial holding of Dr. Heath. The balance was purchased in his own name.

Stuart Paynter, Chief Financial Officer of the Group, has purchased 1,622 ordinary shares of 50p each ("Ordinary Shares") in the Company on 18 January 2019 on the London Stock Exchange at a price of 612.8p. Following this purchase Stuart Paynter holds 3,375 shares representing 0.005% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 
 1.   Details of the person discharging material responsibilities/person 
       closely associated 
 a.   Name                                         Dr. Andrew Heath 
 2.   Reason for the notification 
 a.   Position/status                              Deputy Chairman and Senior Independent 
                                                    Director 
 b.   Initial notification                         Initial notification 
       /amendment 
3.    Details of the issuer, emission allowance, market 
       participant, auction platform, auctioneer or auction 
       monitor 
 a.   Name                                         Oxford BioMedica plc 
 b.   Legal Entity Identifier                      213800S1GVQNXQ15K851 
4.    Details of the transaction(s); section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
 a.   Description of                               Oxford BioMedica plc Ordinary Shares 
       the financial                                of 50p each 
       instrument, type                             GB00BDFBVT43 
       of instrument 
       identification 
       code 
b.    Nature of the                                Purchase of ordinary shares 
       transaction 
c.    Currency                                     GBP - British Pound 
d.    Price(s) and volume(s)                             Price(s)               Volume(s) 
                                 GBP6.16                                          2,000 
e.          Aggregated information                 2,000 
              *    Aggregated volume                GBP6.155038 
                                                    GBP12,310.08 
 
              *    Price 
 
 
              *    Aggregated total 
f.    Date of the transaction                      2019-01-17 
g.    Place of the transaction                     London Stock Exchange, Main Market (XLON) 
 
 
 1.   Details of the person discharging material responsibilities/person 
       closely associated 
 a.   Name                                         Eva Lackner 
 2.   Reason for the notification 
 a.   Position/status                              Person closely associated with Dr. Andrew 
                                                    Heath, Deputy Chairman and Senior Independent 
                                                    Director 
 b.   Initial notification                         Initial notification 
       /amendment 
3.    Details of the issuer, emission allowance, market 
       participant, auction platform, auctioneer or auction 
       monitor 
 a.   Name                                         Oxford BioMedica plc 
 b.   Legal Entity Identifier                      213800S1GVQNXQ15K851 
4.    Details of the transaction(s); section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
 a.   Description of                               Oxford BioMedica plc Ordinary Shares 
       the financial                                of 50p each 
       instrument, type                             GB00BDFBVT43 
       of instrument 
       identification 
       code 
b.    Nature of the                                Purchase of ordinary shares 
       transaction 
c.    Currency                                     GBP - British Pound 
d.    Price(s) and volume(s)                              Price(s)                  Volume(s) 
                                  GBP6.16                                            2,000 
e.          Aggregated information                 2,000 
              *    Aggregated volume                GBP6.155038 
                                                    GBP12,310.08 
 
              *    Price 
 
 
              *    Aggregated total 
f.    Date of the transaction                      2019-01-17 
g.    Place of the transaction                     London Stock Exchange, Main Market (XLON) 
 
 
 1.   Details of the person discharging material responsibilities/person 
       closely associated 
 a.   Name                                         Stuart Paynter 
 2.   Reason for the notification 
 a.   Position/status                              Chief Financial Officer 
 b.   Initial notification                         Initial notification 
       /amendment 
3.    Details of the issuer, emission allowance, market 
       participant, auction platform, auctioneer or auction 
       monitor 
 a.   Name                                         Oxford BioMedica plc 
 b.   Legal Entity Identifier                      213800S1GVQNXQ15K851 
4.    Details of the transaction(s); section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
 a.   Description of                               Oxford BioMedica plc Ordinary Shares 
       the financial                                of 50p each 
       instrument, type                             GB00BDFBVT43 
       of instrument 
       identification 
       code 
b.    Nature of the                                Purchase of ordinary shares 
       transaction 
c.    Currency                                     GBP - British Pound 
d.    Price(s) and volume(s)                             Price(s)               Volume(s) 
                                 GBP6.13                                          1,622 
e.          Aggregated information                 1,622 
              *    Aggregated volume                GBP6.1277218 
                                                    GBP9,939.16 
 
              *    Price 
 
 
              *    Aggregated total 
f.    Date of the transaction                      2019-01-18 
g.    Place of the transaction                     London Stock Exchange, Main Market (XLON) 
 

The issued share capital of the Group is 66,103,528 ordinary 50p shares.

-Ends-

 
 For further information, please contact: 
  Oxford BioMedica plc:                      Tel: [phone] 
   Stuart Paynter, Company Secretary 
 

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 360 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHSFUFSAFUSELF

(END) Dow Jones Newswires

January 18, 2019 05:51 ET (10:51 GMT)